- E-mailSonia.Gavasso@uib.no
- Visitor AddressHaukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
- Postal AddressPostboks 78045020 Bergen
Journal articles
- 2019. Candidate markers for stratification and classification in rheumatoid arthritis. Frontiers in Immunology. 10:1488: 1-8. doi: 10.3389/fimmu.2019.01488
- 2019. Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads. Cytometry Part A. 1-10. doi: 10.1002/cyto.a.23723
- 2019. Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary sjogren's syndrome. Frontiers in Immunology. 10:281: 1-18. doi: 10.3389/fimmu.2019.00281
- 2018. Phosphorylation of intracellular signaling molecules in peripheral blood cells from psoriasis patients on originator or biosimilar infliximab. British Journal of Dermatology. 179: 371-380. doi: 10.1111/bjd.16269
- 2018. Aberrant cell signalling in PBMCs upon IFN-? stimulation in primary Sjogren's syndrome patients associates with type I interferon signature. European Journal of Immunology. 48: 1217-1227. doi: 10.1002/eji.201747213
- 2017. Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories. Scandinavian Journal of Immunology. 86: 165-170. doi: 10.1111/sji.12572
- 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
- 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
- 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
- 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE. 9. doi: 10.1371/journal.pone.0088632
- 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 18: 1116-1124. doi: 10.1177/1352458511434066
- 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 253: 18-19.
- 2012. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 126: 84-89. doi: 10.1111/ane.12026
- 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 203: 134-135.
- 2006. Multiplexed phosphoprotein analysis in immune cells. Acta Neurologica Scandinavica. 113: 58-60. doi: Sesammendrag
- 2005. Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 180: 277-282.
Reports and theses
- 2013. Evaluation of interferon-beta neutralizing antibodies in individual patients with multiple sclerosis based on phospho-specific flow cytometry. University of Bergen.
More information in national current research information system (CRIStin)